R-HCVAD regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Rituximab-Hyper-Cyclophosphamide-Vincristine-Adriamycin-Dexamethasone regimen
Overview
Overview
R-HCVAD regimen refers to a regimen consisting of rituximab, cyclophosphamide, vincristine, doxorubicin (Adriamycin), and dexamethasone used to treat some forms of mantle cell lymphoma.[1]
Regimen
Regimen
RRituximab
CCyclophosphamide
VVincristine (Oncovin)
ADoxorubicin (Adriamycin)
DDexamethasone
References
References
- ↑ 1.0 1.1 Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B; et al. (2005). “High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine”. J Clin Oncol. 23 (28): 7013–23. doi:10.1200/JCO.2005.01.1825. PMID 16145068.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH